Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vitiligo

- PMLiVE

Putting Skin in the Game at AAD 2023

AAD has wrapped up in New Orleans, and the Medscape team have returned home from another successful conference.During the conference, Medscape hosted one educational symposium, Reframing the Management Approach for...

Medscape Education Global

- PMLiVE

LEO Pharma enters clinical trial partnership with ICON

The collaboration will focus on advancing clinical trial execution within medical dermatology

- PMLiVE

Boehringer’s Spevigo receives EC approval for generalised pustular psoriasis flares

Trial showed 54% of patients were free of pustules one week after a single dose

- PMLiVE

UCB’s Epicensus programme highlights need to address psoriasis care gap

The programme was published in Dermatology and Therapy

- PMLiVE

Sanofi and Regeneron’s Dupixent granted EC approval for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

There are no topical treatments specifically developed and approved for moderate-to-severe CHE

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Best practice in UK dermatology care celebrated at second national awards

NHS teams from the Isle of Wight, Northern Ireland and London were among those recognised at the second annual Quality in Care Dermatology Awards

- PMLiVE

Dermavant’s Vtama shows promise in paediatric atopic dermatitis trial

The trial included children aged between two to 17 years and the treatment was well tolerated

- PMLiVE

Almirall granted EMA approval for lebrikizumab in atopic dermatitis

The Marketing Authorization Application is based on three pivotal phase 3 studies

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

- PMLiVE

Incyte’s Opzelura shows significant improvements in phase 3 vitiligo trial

The positive data has been published in The New England Journal of Medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links